Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Suppressor of cytokine signalling-1 (SOCS1) protein negatively regulates cytokine signalling pathways by associating with tyrosine kinases.
• Dysregulation of cytokine signalling is implicated in the pathogenesis of chronic myeloid leukaemia (CML).

Purpose of the Study:

• To investigate the role of SOCS1 gene alterations, specifically mutations and CpG island methylation, in the development and progression of CML.
• To determine if SOCS1 gene silencing through methylation contributes to CML pathogenesis.

Main Methods:

• Analysis of SOCS1 gene mutation status, CpG island methylation, and gene expression in 112 CML samples, 5 cell lines, and 30 controls.
• Utilized mutation analyses, methylation-specific PCR, real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR), and immunocytochemistry.

Main Results:

• No genetic mutations in the SOCS1 gene were detected in CML samples.
• SOCS1 gene hypermethylation was observed in 67% of blastic phase and 46% of chronic phase CML samples.
• SOCS1 methylation was absent in normal controls and CML in molecular remission, correlating with gene expression levels.

Conclusions:

• SOCS1 gene silencing in CML is primarily caused by CpG island hypermethylation, not mutations.
• Reversal of SOCS1 methylation and restoration of gene expression occur in CML molecular remission.
• Loss of SOCS1-mediated negative regulation of cytokine signalling due to methylation may contribute to CML progression.